The Filing Desk

Codexis vs Standard Biotools

Codexis CDXS · Standard Biotools LAB · Life Sciences Tools & Services

Standard Biotools reported revenue of $85 million in fiscal 2025, 1.2 times Codexis' $70 million in fiscal 2025. Codexis' revenue grew 18.6% in its latest year, and Standard Biotools' fell 6.2%. Codexis had an operating margin of -59.3%, against -129.2% at Standard Biotools. Free cash flow was −$24 million at Codexis and −$83 million at Standard Biotools.

Side by side

CodexisStandard Biotools
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$70M$85M
Revenue growth18.6%−6.2%
Revenue growth a year, last 5 years0.4%−9.2%
Gross margin86.7%49.9%
Operating margin−59.3%−129.2%
Net margin−62.5%−87.8%
Free cash flow−$24M−$83M
Free cash flow margin−33.9%−96.8%
Return on capital−189.5%−41.9%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count18.7%8.0%
Last close$1.05$0.61
P/E at the last close—1.8×
Insider trades, last 12 monthssold $933,396bought $11.1 million, sold $0
Piotroski F-score4 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CodexisStandard Biotools
Operating margin
Percent of revenue
CodexisStandard Biotools
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CodexisStandard Biotools

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Codexis and Standard Biotools pages.